Sai Parenterals Q2 FY27 Revenue Up 9% QoQ to ₹196 Cr; PAT ₹11 Cr
Sai Parenterals reported Q2 FY27 revenue of ₹196.1 crore, up 9.0% QoQ. PAT for the quarter was ₹10.5 crore. H1 FY27 revenue reached ₹376.0 crore, ahead of target. The company completed acquisitions of Saicriti Pharma (₹83.83 Cr) and Prathyak Laboratories (₹15 Cr). A new injectable facility is targeted for July 2027 completion.
The announcement includes significant financial performance improvements, strategic acquisitions that are key to future growth, and progress on major capacity expansions and new facilities, all of which are material to investors.
The company reported strong sequential growth in revenue, gross profit, EBITDA, and PAT. Key strategic acquisitions were completed, and major capacity expansion projects are progressing as planned, with future revenue targets ahead of guidance.
Sai Parenterals Limited announced its un-audited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026.
For the second quarter of fiscal year 2027 (Q2 FY27), the company reported revenue from operations of ₹196.1 crore, marking a 9.0% increase quarter-on-quarter (QoQ) from ₹179.9 crore in Q1 FY27. Gross profit stood at ₹93.1 crore, up 26.4% QoQ, with gross margins improving to 47.5% from 40.9% in Q1 FY27, attributed to tighter inventory management and the implementation of a new ERP system with first-in, first-out controls. EBITDA surged by 67.4% QoQ to ₹41.4 crore, with the EBITDA margin at 21.1% compared to 13.7% in Q1 FY27. Profit After Tax (PAT) for the quarter grew 32.7% QoQ to ₹10.5 crore.
For the first half of fiscal year 2027 (H1 FY27), revenue from operations reached ₹376.0 crore, representing approximately 50% of the FY27 revenue target of ₹750 crore, ahead of the guided 45:55 phasing. H1 FY27 PAT stood at ₹18.4 crore.
In strategic developments, the company completed the acquisition of 60% stakes in Saicriti Pharma Private Limited for ₹83.83 crore and Prathyak Laboratories Private Limited for ₹15 crore, utilizing IPO proceeds. The new critical-care injectable facility at Saicriti Pharma is on track for completion in July 2027, with a planned capacity of approximately 154.66 million units, built to EU-GMP and USFDA standards. Group R&D has been consolidated at Sai Prathyak Laboratories, which will start taking external CDMO development contracts over the next two quarters, with revenue expected from FY28. The Unit III expansion at Bhongir is complete, raising production capacity by 81% to 155 million units a month, with output ramping up from Q4 FY27, primarily serving Australia and New Zealand. The Adelaide facility is set to begin operations in January 2027, with commercial supply expected around April 2027. Noumed's contracted Australian OTC supply has risen to AUD 232 million (approximately ₹1,506 crore) following a renewal of an agreement.
Commenting on the results, Mr. Anil Kumar Karusala, Chairman and Managing Director, highlighted the sequential improvement in profitability, revenue growth, margin expansion, and progress on capex projects, expressing confidence in meeting the FY27 targets and positioning the company for performance growth in FY28.
What to do with a filing like this
Sai Parenterals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Sai Parenterals Limited. Read the original for the full detail.